HROW Stock Overview
An eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for HROW from our risk checks.
Harrow, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$42.44 |
| 52 Week High | US$59.23 |
| 52 Week Low | US$8.72 |
| Beta | 0.76 |
| 11 Month Change | -24.78% |
| 3 Month Change | 2.71% |
| 1 Year Change | 361.81% |
| 33 Year Change | 315.67% |
| 5 Year Change | 583.41% |
| Change since IPO | 390.71% |
Recent News & Updates
Harrow: Spotlight On IHEEZO
Nov 16Harrow's Focus - Reviving Old Drugs In A Crowded Market
Oct 02Harrow: 3 Business Models, One Mission
Sep 10Recent updates
Harrow: Spotlight On IHEEZO
Nov 16Harrow's Focus - Reviving Old Drugs In A Crowded Market
Oct 02Harrow: 3 Business Models, One Mission
Sep 10Borrowing Cash To Burn It: The Curious Case Of Harrow
Aug 21Harrow: The Bull Thesis Is On Track, But Short-Term Challenges Loom
May 02Harrow's Drug Iheezo Is Off To A Great Start
Feb 19Harrow: Temporary Disruption In Stock Price Creates Excellent Opportunity
Jan 30Harrow sells non‑ophthalmic compounding business, terms undisclosed
Oct 05Harrow Health soars ~27% on FDA nod of anesthesia gel for the surface of the eye
Sep 27SRK Capital - Harrow Health: Market Missing The Forest For The Trees
Aug 19These 4 Measures Indicate That Harrow Health (NASDAQ:HROW) Is Using Debt Extensively
Aug 11
Buy Deep Moated, Fast Growing, Superbly Managed Harrow Health Ahead Of New Product Launch
May 23Does Harrow Health (NASDAQ:HROW) Have A Healthy Balance Sheet?
May 12Is Harrow Health (NASDAQ:HROW) A Risky Investment?
Dec 15Does Harrow Health (NASDAQ:HROW) Have A Healthy Balance Sheet?
Aug 24Shareholder Returns
| HROW | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -18.1% | -3.8% | -1.0% |
| 1Y | 361.8% | 9.8% | 30.3% |
Return vs Industry: HROW exceeded the US Pharmaceuticals industry which returned 8.7% over the past year.
Return vs Market: HROW exceeded the US Market which returned 30.4% over the past year.
Price Volatility
| HROW volatility | |
|---|---|
| HROW Average Weekly Movement | 9.4% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: HROW has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: HROW's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 315 | Mark Baum | www.harrow.com |
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis.
Harrow, Inc. Fundamentals Summary
| HROW fundamental statistics | |
|---|---|
| Market cap | US$1.41b |
| Earnings (TTM) | -US$33.41m |
| Revenue (TTM) | US$169.14m |
8.9x
P/S Ratio-45.2x
P/E RatioIs HROW overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HROW income statement (TTM) | |
|---|---|
| Revenue | US$169.14m |
| Cost of Revenue | US$46.41m |
| Gross Profit | US$122.73m |
| Other Expenses | US$156.13m |
| Earnings | -US$33.41m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.94 |
| Gross Margin | 72.56% |
| Net Profit Margin | -19.75% |
| Debt/Equity Ratio | 322.9% |
How did HROW perform over the long term?
See historical performance and comparison